Clinical trial
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or…
NCT02304367 · Kyowa Kirin, Inc., Industry · Completed
Key facts
| NCT number | NCT02304367 |
|---|---|
| Title | Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) |
| Official title | A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia |
| Lead sponsor | Kyowa Kirin, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS) |
| Intervention type | Biological |
| Interventions | Burosumab |
| Enrollment | 17 |
| Start date | Mar 24, 2015 |
| Primary completion | Jul 27, 2017 |
| Completion | Jan 21, 2021 |
| First posted | Dec 1, 2014 |
| Last update posted | May 6, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: